Results 31 to 40 of about 6,775 (167)

Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab [PDF]

, 2022
OBJECTIVE: Secondary inefficacy with infusion reactions and anti-drug antibodies (secondary non-depletion nonresponse, 2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and
Vital, EM, Arnold, J, Hewins, P, Dass, S, Rhodes, B, Twigg, S, Chakravorty, M, Jones, CH, Ehrenstein, M, Md Yusof, MY, Courtney, P   +10 more
core   +3 more sources

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

HemaSphere, 2023
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL).
William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus   +18 more
doaj   +1 more source

Venetoclax and obinutuzumab in patients with CLL and coexisting conditions [PDF]

, 2019
Background: The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.
Liberati, A. M., Dixon, M., Fogliatto, L. M., Le Dû, K., Niemann, C. U., Humphrey, K., Humerickhouse, R., Fischer, K., Robinson, S., Pinilla-Ibarz, J., Goede, V., Tandon, M., Kipps, T. J., Tausch, E., Ritgen, M., Opat, S., Warburton, S., Eichhorst, B., Kreuzer, K. A., Al-Sawaf, O., Fink, A. M., Weinkove, R., Sivcheva, L., Stilgenbauer, S., Robrecht, S., Hallek, M., Langerak, A. W., Boettcher, S., Wendtner, C. M., Bahlo, J., Samoylova, O., Mobasher, M.   +31 more
core   +1 more source

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis

Case Reports in Oncology
Introduction: Obinutuzumab, an anti-CD20 antibody, is widely used in the treatment of B-cell lymphomas. While diarrhea is a known side effect, obinutuzumab-induced inflammatory bowel disease (IBD)-like conditions are rarely reported.
Nadav Weijel, Safwat Odeh, Amjad Mousa, Nina Nazarov, Olga Zelman, Ilana Levy Yurkovski   +5 more
doaj   +1 more source

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations [PDF]

, 2016
Introduction: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody (MoAb) with a higher affinity for CD20 epitope. It was approved by the United States Food and Drug Administration (FDA) in November 2013 for use in combination ...
M. Sciumè, N. Orofino, A. Cortelezzi, G. Reda, R. Cassin, B. Fattizzo   +5 more
core   +1 more source

Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia [PDF]

, 2021
First obinutuzumab application is associated with infusion related reactions (IRRs) that may discourage further continuation of the drug. During our clinical practice we have observed that chronic lymphocytic leukemia (CLL) patients with autoimmune ...
Jakšić, Ozren, Piršić, Mario, Lucijanić, Marko, Vrkljan Vuk, Anamarija, Jonjić, Željko, Prka, Željko, Fazlić Džankić, Amina, Štoos-Veić, Tajana, Ivić, Marija, Pejša, Vlatko, Mitrović, Zdravko   +10 more
core   +1 more source

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial [PDF]

, 2019
Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia.
Gribben, John G., Novak, Jan, Ben-Yehuda, Dina, Zhou, Cathy, Samoilova, Olga, DEMİRKAN, FATİH, Flinn, Ian W., Hsu, Emily, Anz, Bertrand, Larratt, Loree, Moreno, Carol, Lih, Chih-Jian, Simkovic, Martin, Greil, Richard, Strugov, Vladimir, James, Danelle F., Tedeschi, Alessandra, Gill, Devinder, Clow, Fong, Styles, Lori   +19 more
core   +1 more source

Obinutuzumab Effective in Follicular Lymphoma, but at a Cost [PDF]

, 2017
In a phase III trial involving more than 1,200 patients with follicular lymphoma, obinutuzumab plus chemotherapy reduced the risk of disease progression, relapse, or death by 34% compared with rituximab plus chemotherapy.

core   +1 more source

From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates

Advanced Materials, EarlyView.
Conjugation converts potent antibodies into underexposed carriers. This perspective defines the antibody exposure deficit and maps a mechanism‐first design space from payload‐first to antibody‐first ADC architectures, integrating DAR, linker chemistry, and Fc engineering to guide rational design of constructs that balance targeted cytotoxicity with ...
Xavier Pivot, Sebastian Jung, Sébastien Harlepp, Alexandre Detappe   +3 more
wiley   +1 more source

Obinutuzumab in hematologic malignancies: Lessons learned to date. [PDF]

, 2015
The routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Klein, Christian, Davies, Andrew, Sehn, Laurie H., Gilles Salles, Sehn, Laurie H, Cartron, Guillaume, Illidge, Tim; id_orcid, Salles, Gilles, Sehn, Laurie, Tim Illidge, Laurie H. Sehn, Guillaume Cartron, Christian Klein, Illidge, Tim, Andrew Davies   +14 more
core   +1 more source